Liquid biopsy for lung cancer: what a blood test can tell you
A liquid biopsy can look for treatment-relevant cancer DNA in a blood sample. It is useful when tissue is limited or when cancer changes during treatment. A negative blood result often needs a follow-up plan because some tumors release too little DNA for the test to detect.
On this page
What a liquid biopsy actually measures
Some lung cancers release small fragments of DNA into the bloodstream. A blood-based molecular test can examine these fragments for changes that may help select treatment, such as certain EGFR mutations or gene fusions. The report usually describes the alterations found and the test's coverage.
This is a different question from establishing the cancer's tissue diagnosis. A pathology sample tells the team what type of cancer is present and can provide information that a blood DNA panel does not measure. Patients often need both forms of information to make a treatment decision.
When blood testing can help
For advanced non-small cell lung cancer, a liquid biopsy may be useful when the existing biopsy is small, obtaining another tissue sample would be difficult, or molecular results are needed promptly. The clinician can decide whether to order blood and tissue testing together or use one to supplement the other.
Ask what decision the test is intended to support. Selecting a first treatment, investigating progression on a targeted drug and monitoring a known alteration are different tasks. The laboratory panel and the timing of the sample should match the task.
How to use a positive result
A relevant alteration can help the oncologist identify a targeted treatment or a clinical trial. The exact wording matters: an EGFR exon 19 deletion and an EGFR exon 20 insertion, for example, lead to different treatment discussions. A variant of uncertain significance usually does not identify a treatment by itself.
Bring the full report, including the laboratory methods and any interpretation notes. The team will place the finding alongside the diagnosis, stage, previous treatment and available medicines. A list of drug names printed beside a result is a starting point for this review.
What happens when the blood test is negative
A negative result may mean that the test found no relevant alteration in the DNA available in the sample. Some tumors shed little DNA, and a panel may not cover every type of alteration equally well. Tissue testing can therefore still find a useful result after blood testing is negative.
The practical next question is whether adequate stored tissue is available. If it is, ask whether it can be tested without another procedure. If a new biopsy is being considered, discuss which site is safest to sample and whether the result is likely to change treatment.
Retesting when a treatment stops working
A cancer can acquire changes that allow it to grow despite a targeted drug. Retesting at progression may identify a resistance mechanism and help the team compare another drug, a combination or a trial. A new blood sample can sometimes provide this information with relatively little disruption.
Tissue becomes especially valuable if the team suspects a change in the cancer's cell type. Include the latest scans and a timeline of treatment response when requesting reassessment. These show whether growth is limited to one area or occurring throughout the body.
Blood tests after surgery need a specific purpose
After treatment for early lung cancer, tests that look for very small amounts of cancer DNA are being studied as a way to assess residual disease and recurrence risk. Their role depends on the assay and the clinical setting. Your usual imaging and follow-up appointments remain part of the plan.
Before paying for a test, ask what would happen after a positive result and what would happen after a negative one. A useful discussion includes whether the result would change a recommended treatment, lead to a trial or simply provide additional information at that point.
Prepare a report that another team can interpret
Keep the blood test date, the complete molecular report, the pathology diagnosis and the names and dates of all cancer treatments together. Record whether you were responding to treatment or experiencing progression when the sample was collected. An older result may still be useful, but its date affects how it is interpreted.
If another laboratory is proposed, ask which unanswered question it will address. This helps avoid repeating a similar panel when the real gap is a tissue diagnosis, a missing fusion assay or an updated scan.
Sources and references: [2]
Arrange a molecular treatment review in Shanghai
EastMedGo can help organize your records for a Shanghai lung cancer review, starting with the specific decision you need to make. Our pathology and molecular review overview explains how these reports fit into treatment assessment.
Send a brief account of the current problem through EastMedGo and ask how to provide your reports for review. We can help clarify which existing samples or documents the receiving team wants, coordinate an appointment request and plan the practical steps around it. Confirm any new testing with that team before arranging travel.
Common questions
Does a negative liquid biopsy rule out a targetable lung cancer mutation?
No. A tumor may release too little DNA into the blood for detection. Ask whether stored tissue can be tested or whether a new biopsy would help answer the treatment question.
Can a liquid biopsy replace the original lung biopsy?
Blood molecular testing can support treatment selection, while tissue or cell samples establish the diagnosis and cancer type. The team decides how to obtain the information needed when a tissue procedure is difficult.
Sources and references: [2]
Should I repeat the same test before a second opinion?
Bring the existing complete report first. The reviewing team can identify whether it needs a newer sample, broader coverage or tissue testing, which can save an unnecessary repeat.
Sources and references
- Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care
- Biomarker Testing for Cancer Treatment
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.